HENLIUS Shares Rise Nearly 5% in Afternoon Session on AACR Data Debut

Stock News04-24

HENLIUS (02696) saw its shares climb close to 5% during afternoon trading. At the time of writing, the stock was up 3.91%, trading at HK$82.35, with a turnover of HK$61.73 million. The movement follows the company's recent presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, where it unveiled preclinical research data for the first time on its investigational novel CD3×CD28×STEAP1 targeting trispecific T-cell engager (TCE), HLX3902, via a poster session. The company is actively advancing the platform's application in more "immune-desert" types of solid tumors and has already developed over five early-stage innovative molecules based on this platform. A recent research report from Western Securities projected the company's revenue for 2026-2028 to be RMB 7.397 billion, RMB 8.039 billion, and RMB 9.535 billion, representing year-on-year growth of 11.0%, 8.7%, and 18.6%, respectively. The report noted that HENLIUS's innovative pipeline is yielding significant results, with multiple catalysts expected from clinical data readouts and potential business development opportunities, further bolstered by the overseas expansion of its biosimilar products enhancing performance. The firm maintained a "Buy" rating on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126189239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 13:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126189239","market":"us","top_or_hot":-1,"title":"HENLIUS Shares Rise Nearly 5% in Afternoon Session on AACR Data Debut","media":"Stock News","content":"<p>HENLIUS (02696) saw its shares climb close to 5% during afternoon trading. At the time of writing, the stock was up 3.91%, trading at HK$82.35, with a turnover of HK$61.73 million. The movement follows the company's recent presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, where it unveiled preclinical research data for the first time on its investigational novel CD3×CD28×STEAP1 targeting trispecific T-cell engager (TCE), HLX3902, via a poster session. The company is actively advancing the platform's application in more \"immune-desert\" types of solid tumors and has already developed over five early-stage innovative molecules based on this platform. A recent research report from Western Securities projected the company's revenue for 2026-2028 to be RMB 7.397 billion, RMB 8.039 billion, and RMB 9.535 billion, representing year-on-year growth of 11.0%, 8.7%, and 18.6%, respectively. The report noted that HENLIUS's innovative pipeline is yielding significant results, with multiple catalysts expected from clinical data readouts and potential business development opportunities, further bolstered by the overseas expansion of its biosimilar products enhancing performance. The firm maintained a \"Buy\" rating on the stock.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS Shares Rise Nearly 5% in Afternoon Session on AACR Data Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS Shares Rise Nearly 5% in Afternoon Session on AACR Data Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-24 13:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) saw its shares climb close to 5% during afternoon trading. At the time of writing, the stock was up 3.91%, trading at HK$82.35, with a turnover of HK$61.73 million. The movement follows the company's recent presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, where it unveiled preclinical research data for the first time on its investigational novel CD3×CD28×STEAP1 targeting trispecific T-cell engager (TCE), HLX3902, via a poster session. The company is actively advancing the platform's application in more \"immune-desert\" types of solid tumors and has already developed over five early-stage innovative molecules based on this platform. A recent research report from Western Securities projected the company's revenue for 2026-2028 to be RMB 7.397 billion, RMB 8.039 billion, and RMB 9.535 billion, representing year-on-year growth of 11.0%, 8.7%, and 18.6%, respectively. The report noted that HENLIUS's innovative pipeline is yielding significant results, with multiple catalysts expected from clinical data readouts and potential business development opportunities, further bolstered by the overseas expansion of its biosimilar products enhancing performance. The firm maintained a \"Buy\" rating on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"","article_id":"1126189239","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126189239","pubTimestamp":1777009586,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) saw its shares climb close to 5% during afternoon trading. At the time of writing, the stock was up 3.91%, trading at HK$82.35, with a turnover of HK$61.73 million. The movement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","VXUS":"国际股票ETF-Vanguard","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4588":"碎股","02696":"复宏汉霖","BK1161":"生物科技","BK4585":"ETF&股票定投概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC"},"translate_title":"AACR数据公布后，复宏汉霖股价下午上涨近5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1,"VXUS":1},"content_text":"HENLIUS (02696) saw its shares climb close to 5% during afternoon trading. At the time of writing, the stock was up 3.91%, trading at HK$82.35, with a turnover of HK$61.73 million. The movement follows the company's recent presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, where it unveiled preclinical research data for the first time on its investigational novel CD3×CD28×STEAP1 targeting trispecific T-cell engager (TCE), HLX3902, via a poster session. The company is actively advancing the platform's application in more \"immune-desert\" types of solid tumors and has already developed over five early-stage innovative molecules based on this platform. A recent research report from Western Securities projected the company's revenue for 2026-2028 to be RMB 7.397 billion, RMB 8.039 billion, and RMB 9.535 billion, representing year-on-year growth of 11.0%, 8.7%, and 18.6%, respectively. The report noted that HENLIUS's innovative pipeline is yielding significant results, with multiple catalysts expected from clinical data readouts and potential business development opportunities, further bolstered by the overseas expansion of its biosimilar products enhancing performance. The firm maintained a \"Buy\" rating on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126189239","isCrawlerRequest":true}